Table 3 Determinants of adjuvant treatment choice stratified by AT type

Male sex, n (%)

284 (56.0)

0.68

(0.41, 1.13)

0.13

0.51

(0.24, 1.09)

0.08

Insurance coverage, n (%)

 Commercial

301 (59.4)

1.00

1.00

 Medicare

173 (34.1)

0.90

(0.49, 1.62)

0.72

0.63

(0.25, 1.55)

0.31

 Medicaid/no insurance

67 (13.2)

0.43

(0.22, 0.84)

 < 0.05 *

0.34

(0.10, 1.15)

0.08

Disease substage at resection, n (%)

 Stage IIIA

168 (33.1)

1.00

 Stage IIIB/C/D

339 (66.9)

1.82

(1.09, 3.05)

 < 0.05 *

1.22

(0.55, 2.69)

0.63

ECOG-PS after resection, n (%)

 ECOG-PS 0/1

416 (82.0)

1.00

 ECOG-PS 2/3

70 (13.8)

0.41

(0.22, 0.79)

 < 0.01 *

0.16

(0.04, 0.63)

 < 0.01 *

Comorbidities, n (%)

 Coronary artery disease/myocardial infarction

41 (8.1)

0.49

(0.24, 0.98)

 < 0.05 *

1.36

(0.47, 3.94)

0.58

Pathology characteristics, n (%)

 Ulceration

268 (52.9)

1.31

(0.79, 2.16)

0.30

1.38

(0.63, 3.00)

0.42

 Lymphovascular invasion

211 (41.6)

1.45

(0.85, 2.46)

0.17

1.58

(0.71, 3.52)

0.26

Baseline LDH level, n (%)

 Normal range/not tested

368 (72.6)

1.00

 Above upper limit of normal

139 (27.4)

1.01

(0.55, 1.84)

0.98

1.35

(0.56, 3.24)

0.51

Treatment and type of resection, n (%)

 Treatment at initial resection

469 (92.5)

1.00

 Treatment after resection for disease recurrence

35 (6.9)

0.44

(0.19, 1.05)

0.06

0.63

(0.15, 2.58)

0.52

LN dissection, n (%)

 Elective LN dissection

28 (5.5)

1.00

 Complete LN dissection

378 (74.6)

1.33

(0.50, 3.58)

0.57

1.62

(0.30, 8.85)

0.57

 SLN biopsy only

96 (18.9)

2.53

(0.81, 7.85)

0.11

2.63

(0.39, 17.76)

0.32

Radiotherapy after resection, n (%)

132 (26.0)

0.75

(0.43, 1.33)

0.32

0.96

(0.40, 2.27)

0.92

Use of steroids after resection, n (%)

53 (10.5)

0.56

(0.25, 1.22)

0.14

1.32

(0.44, 3.93)

0.62